Noah Hahn
Experienced in Hypophosphatemia

Dr. Noah Hahn

Oncology
Johns Hopkins Medicine
Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 4, Floor 4, 
Baltimore, MD 
Offers Telehealth
Experienced in Hypophosphatemia
Johns Hopkins Medicine
Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 4, Floor 4, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group.

Dr. Hahn is rated as an Experienced provider by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

His clinical research consists of co-authoring 156 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hypophosphatemia.

Residency
Duke University Medical Center, Internal Medicine, 2003
Specialties
Oncology
Licenses
Internal Medicine in DC
Fellowships
Indiana University Health and Hospitals, Medical Oncology, 2006
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Johns Hopkins Outpatient Center
601 North Caroline Street, Floor 4, Floor 4, Baltimore, MD 21287
Call: 410-955-6100
Other Locations
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
10803 Falls Road, Pavilion III STE 1500, Lutherville, MD 21093
Call: 410-583-2970

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drugs: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Study Phase: Phase 2
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Berzosertib, Cisplatin, Gemcitabine Hydrochloride
Study Phase: Phase 2
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Vorinostat
Study Phase: Phase 1
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 22, 2024
Intervention Type: Drug
Study Drug: HER2/41BB Bispecific
Study Phase: Phase 1
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217
UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217
Enrollment Status: Completed
Publish Date: September 29, 2023
Intervention Type: Other
Study Phase: Not Applicable
View 7 Less Clinical Trials

156 Total Publications

Intratumoral expression of a composite B cell / CD8 T cell biomarker stratifies overall survival by ctDNA status and benefit from adjuvant immunotherapy in high risk, muscle invasive urothelial carcinoma.
Intratumoral expression of a composite B cell / CD8 T cell biomarker stratifies overall survival by ctDNA status and benefit from adjuvant immunotherapy in high risk, muscle invasive urothelial carcinoma.
Journal: The Journal of urology
Published: October 27, 2025
View All 156 Publications
Similar Doctors
Distinguished in Hypophosphatemia
Dr. Michael A. Auerbach
Hematology Oncology | Hematology | Oncology
Distinguished in Hypophosphatemia
Dr. Michael A. Auerbach
Hematology Oncology | Hematology | Oncology

American Oncology Partners PA

5233 King Ave, Suite 308, 
Baltimore, MD 
 (7.7 miles away)
410-780-4050
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Auerbach is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Auerbach is rated as a Distinguished provider by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Iron Deficiency Anemia, Anemia, Hypophosphatemia, and Childhood Iron Deficiency Anemia. Dr. Auerbach is currently accepting new patients.

Experienced in Hypophosphatemia
Dr. Timothy L. Cannon
Oncology | Hematology | Hematology Oncology
Experienced in Hypophosphatemia
Dr. Timothy L. Cannon
Oncology | Hematology | Hematology Oncology

Inova Health Care Services

3300 Gallows Rd, 
Falls Church, VA 
 (45.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Timothy Cannon is an Oncologist and a Hematologist in Falls Church, Virginia. Dr. Cannon is rated as a Distinguished provider by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Cholangiocarcinoma (Bile Duct Cancer). Dr. Cannon is currently accepting new patients.

Experienced in Hypophosphatemia
Dr. John F. Deeken
Oncology | Hematology Oncology
Experienced in Hypophosphatemia
Dr. John F. Deeken
Oncology | Hematology Oncology

Inova Health Care Services

8081 Innovation Park Dr, 
Fairfax, VA 
 (45.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Deeken is an Oncologist and a Hematologist Oncology provider in Fairfax, Virginia. Dr. Deeken is rated as an Advanced provider by MediFind in the treatment of Hypophosphatemia. His top areas of expertise are Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, and Oral Squamous Cell Carcinoma. Dr. Deeken is currently accepting new patients.

VIEW MORE HYPOPHOSPHATEMIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hahn's expertise for a condition
ConditionClose
  • Elite
  • Bladder Cancer
    Dr. Hahn is
    Elite
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Muscle Invasive Bladder Cancer
    Dr. Hahn is
    Elite
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Upper Tract Urothelial Carcinoma (UTUC)
    Dr. Hahn is
    Elite
    . Learn about Upper Tract Urothelial Carcinoma (UTUC).
    See more Upper Tract Urothelial Carcinoma (UTUC) experts
  • Urothelial Cancer
    Dr. Hahn is
    Elite
    . Learn about Urothelial Cancer.
    See more Urothelial Cancer experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Hahn is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Hahn is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. Hahn is
    Distinguished
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
  • Renal Cell Carcinoma (RCC)
    Dr. Hahn is
    Distinguished
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • WT1-Related Wilms Tumor Syndromes
    Dr. Hahn is
    Distinguished
    . Learn about WT1-Related Wilms Tumor Syndromes.
    See more WT1-Related Wilms Tumor Syndromes experts
  • Advanced
  • Clear Cell Sarcoma
    Dr. Hahn is
    Advanced
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. Hahn is
    Advanced
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Prostate Cancer
    Dr. Hahn is
    Advanced
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Teratoma of the Mediastinum
    Dr. Hahn is
    Advanced
    . Learn about Teratoma of the Mediastinum.
    See more Teratoma of the Mediastinum experts
  • Testicular Cancer
    Dr. Hahn is
    Advanced
    . Learn about Testicular Cancer.
    See more Testicular Cancer experts
  • Wilms Tumor
    Dr. Hahn is
    Advanced
    . Learn about Wilms Tumor.
    See more Wilms Tumor experts
  • Experienced
  • Choriocarcinoma
    Dr. Hahn is
    Experienced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Dehydration
    Dr. Hahn is
    Experienced
    . Learn about Dehydration.
    See more Dehydration experts
  • Familial Prostate Cancer
    Dr. Hahn is
    Experienced
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Hemolytic Transfusion Reaction
    Dr. Hahn is
    Experienced
    . Learn about Hemolytic Transfusion Reaction.
    See more Hemolytic Transfusion Reaction experts
  • Hypophosphatemia
    Dr. Hahn is
    Experienced
    . Learn about Hypophosphatemia.
    See more Hypophosphatemia experts
  • Lymphoid Hyperplasia
    Dr. Hahn is
    Experienced
    . Learn about Lymphoid Hyperplasia.
    See more Lymphoid Hyperplasia experts
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.